| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
BI-689648 targets aldosterone synthase (CYP11B2), an enzyme involved in the synthesis of aldosterone, a key regulator of blood pressure and fluid balance. It is a highly selective inhibitor with an IC₅₀ of 2.1 nM for CYP11B2. It shows 150-fold selectivity over CYP11B1 (cortisol synthase) with an IC₅₀ of 310 nM.
|
|---|---|
| ln Vitro |
BI 689648 has significant selectivity in vitro when compared to FAD and LCI699; its IC50 for CYP11B2 is 2.1 nM, and its selectivity factor is 149 higher than that of CYP11B1. Comparatively, FAD286 shows an IC50 against CYP11B2 that is comparable to that of BI 689648 (2.5 nM); but, due to its increased efficacy against CYP11B1 (94 nM), it has a comparatively small selectivity factor of 38, which is about 4-fold lower [1].
In vitro, BI-689648 potently inhibits aldosterone synthase (CYP11B2) with an IC₅₀ of 2.1 nM. It shows 150-fold selectivity over CYP11B1, with an IC₅₀ of 310 nM. It is a valuable tool for studying aldosterone synthesis and its role in cardiovascular diseases. |
| ln Vivo |
Following oral treatment to cynomolgus monkeys, peak plasma concentrations of BI 689648 (5 mg/kg) are approximately 500 nM. For BI 689648 (aldosterone EC50=2 nM), substantial increases in 11-DOC were only seen at plasma concentrations >2000 nM or aldosterone EC50 >1000-fold, whereas FAD286 demonstrated a ~100-fold window. BI 689648 has modest effects on 11-DC and only at very high plasma concentrations (~10 μM) [1].
In vivo, BI-689648 has been studied for its potential in treating hypertension and other cardiovascular diseases. By inhibiting aldosterone synthase, it reduces aldosterone levels and lowers blood pressure. It is orally active. |
| Enzyme Assay |
The in vitro enzyme assay for BI-689648 measures the inhibition of CYP11B2 and CYP11B1 activity. Recombinant enzymes are incubated with the compound and a substrate, and the production of aldosterone or cortisol is quantified. IC₅₀ values are calculated.
|
| Cell Assay |
In vitro cell-based assays for BI-689648 are performed using cell lines that express CYP11B2, such as adrenocortical cells. Cells are treated with BI-689648, and aldosterone production is measured. The compound's selectivity for CYP11B2 over CYP11B1 is confirmed.
|
| Animal Protocol |
In vivo animal experiments for BI-689648 have been conducted in rodent models of hypertension. Animals are administered the compound orally, and blood pressure is measured. Aldosterone levels in plasma and urine are assessed to confirm target engagement. The compound's effects on electrolyte balance and renal function are also evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of BI-689648 have been characterized in preclinical species. It is orally active. Detailed PK parameters such as half-life, clearance, and oral bioavailability are determined from plasma concentration-time profiles.
|
| Toxicity/Toxicokinetics |
Toxicological data for BI-689648 are limited. In standard preclinical safety assessments, it would be evaluated for potential off-target effects and general toxicity. The compound is intended for research use only and not for therapeutic use in humans.
|
| References | |
| Additional Infomation |
BI-689648 is a highly selective aldosterone synthase inhibitor that has been studied for the treatment of hypertension. It shows high selectivity for CYP11B2 over CYP11B1. It has not been approved for clinical use.
|
| Molecular Formula |
C16H18N4O2
|
|---|---|
| Molecular Weight |
298.339723110199
|
| Exact Mass |
298.142
|
| CAS # |
1633009-87-6
|
| PubChem CID |
86305663
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
392
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C(N)=O)C2C(=CC(C3=CC(COC)=CN=C3)=CN=2)CCC1
|
| InChi Key |
DJFDCVNQDFICKV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H18N4O2/c1-22-10-11-5-13(8-18-7-11)14-6-12-3-2-4-20(16(17)21)15(12)19-9-14/h5-9H,2-4,10H2,1H3,(H2,17,21)
|
| Chemical Name |
6-(5-(methoxymethyl)pyridin-3-yl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
| Synonyms |
BI 689648; BI-689648; BI689648.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~30 mg/mL (~100.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.38 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3519 mL | 16.7594 mL | 33.5188 mL | |
| 5 mM | 0.6704 mL | 3.3519 mL | 6.7038 mL | |
| 10 mM | 0.3352 mL | 1.6759 mL | 3.3519 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA